Skip to main content
Caplight Logo









Desentum Oy

Desentum Oy

Private
EspooHealthcare & Life Scienceshttps://desentum.fi/

Last Round

VC Round

Apr 27, 2026

Total Funding Raised

$28.9M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Desentum Oy is a clinical-stage biopharmaceutical company that develops novel allergen immunotherapy products designed to switch the immune system's response to allergens from hypersensitivity to tolerance.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

allergen immunotherapyallergy vaccinerecombinant hypoallergensallergy shotsbiopharmaceuticalimmune toleranceclinical-stage biotechbirch pollen allergyfood allergy treatmentimmunotherapy platformdrug developmentbiotech startupallergy immunotherapyAIT

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Desentum Oy Comparables

Compare Desentum Oy with similar companies based on industry and business-model similarity.

Desentum Oy comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Angany
81%
Aravax
81%
Mabylon AG
78%

Desentum Oy Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundApr 27, 2026
Series CFeb 20, 2024
Series AJan 21, 2022
VC RoundNov 1, 2019
GrantOct 29, 2018
Crowdfunding
Nov 29, 2017

Desentum Oy Investors

Notable investors and investment history

Desentum Oy investors
InvestorRounds
Cascara VenturesSeries A
VTT HoldingSeries A
European Innovation Council FundGrant
SpringvestVC Round, Series A, Series C

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 27, 2026

    $21.15M round led by Springvest

  • Jul 18, 2025

    Grew 33% QoQ from 9 to 12 employees.

Desentum Oy Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Desentum Oy Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Desentum Oy's valuation, stock price, and market status.

Firmographic Details

HeadquartersEspoo
Employee Range13
Year Founded2011
Last FundingApr 27, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?